<p>(A) Application of the cGMP analog 8-Br-cGMP (1 mM) to the axonal endings of type 4 CBCs (A<sub>1</sub>) reduced the duration of the slow component of the glutamate response (A<sub>3</sub>). (A<sub>4</sub>, A<sub>5</sub>) While the charge transferred during the response was significantly reduced by 8-Br-cGMP, this cGMP analog did not affect the maximum amplitude of the glutamate response. (B) Addition of the sGC inhibitor ODQ (100 µM) to the internal solution of the recording pipette prevented the action of NO on the slow component of the glutamate response in type 4 CBCs (B<sub>3</sub>). Note the previously recorded ON CBC to the left (B<sub>2</sub>). (B<sub>4</sub>, B<sub>5</sub>) Neither the charge transferred during the glutamate res...
<p><b>A.</b> Concentration-cGMP response curve for BAY 60-7550 in the presence of BAY 41-2272 in imm...
Riod of 5 minutes before (top, n = 1075 events) and after the application of 1 μM TGOT (bottom, n = ...
<p>(a) Treatment with a cGMP agonist (8-Br-cGMP, 1 μM) or PKG agonist (8-pCPT-cGMP, 1 μM) alone. The...
<p>(A) Perfusion of the axonal terminals of type 4 CBCs with the NO precursor L-arginine (1 mM) sign...
<p>(A) NO suppresses evoked release (eEJC) over a time course of 55 min. Insets show representative ...
<p>(A) Comparison of the recovery of the amplitude of the fast, kainate receptor-dependent component...
These studies were designed to examine the differential effect of nitric oxide (NO) and cGMP on glut...
<p>(A) A representative experiment for a burst firing neuron is shown. Glutamate was uncaged using a...
Nitric oxide (NO) is involved in retinal signal processing, but its cellular actions are only partly...
We compared the effects of sodium nitroprusside (SNP), and of 8-bromo guanosine 3',5'-cyclic monopho...
<p><b>A)</b> Examples of how intra-activation open probability (P<sub>O</sub>) increased as glutamat...
In brain and other tissues, nitric oxide (NO) operates as a diffusible second messenger that stimula...
<p>Normalized <b>(A, B)</b> and absolute <b>(C, D)</b> O<sub>2</sub> consumption rates (OCRs) after ...
We examined the mechanisms of NO action on transmitter release in neuromuscular preparations of the ...
<p>The profiles of a nNOS-positive NOAC (red) and a type 4 OFF CBC (green) are projected onto the nN...
<p><b>A.</b> Concentration-cGMP response curve for BAY 60-7550 in the presence of BAY 41-2272 in imm...
Riod of 5 minutes before (top, n = 1075 events) and after the application of 1 μM TGOT (bottom, n = ...
<p>(a) Treatment with a cGMP agonist (8-Br-cGMP, 1 μM) or PKG agonist (8-pCPT-cGMP, 1 μM) alone. The...
<p>(A) Perfusion of the axonal terminals of type 4 CBCs with the NO precursor L-arginine (1 mM) sign...
<p>(A) NO suppresses evoked release (eEJC) over a time course of 55 min. Insets show representative ...
<p>(A) Comparison of the recovery of the amplitude of the fast, kainate receptor-dependent component...
These studies were designed to examine the differential effect of nitric oxide (NO) and cGMP on glut...
<p>(A) A representative experiment for a burst firing neuron is shown. Glutamate was uncaged using a...
Nitric oxide (NO) is involved in retinal signal processing, but its cellular actions are only partly...
We compared the effects of sodium nitroprusside (SNP), and of 8-bromo guanosine 3',5'-cyclic monopho...
<p><b>A)</b> Examples of how intra-activation open probability (P<sub>O</sub>) increased as glutamat...
In brain and other tissues, nitric oxide (NO) operates as a diffusible second messenger that stimula...
<p>Normalized <b>(A, B)</b> and absolute <b>(C, D)</b> O<sub>2</sub> consumption rates (OCRs) after ...
We examined the mechanisms of NO action on transmitter release in neuromuscular preparations of the ...
<p>The profiles of a nNOS-positive NOAC (red) and a type 4 OFF CBC (green) are projected onto the nN...
<p><b>A.</b> Concentration-cGMP response curve for BAY 60-7550 in the presence of BAY 41-2272 in imm...
Riod of 5 minutes before (top, n = 1075 events) and after the application of 1 μM TGOT (bottom, n = ...
<p>(a) Treatment with a cGMP agonist (8-Br-cGMP, 1 μM) or PKG agonist (8-pCPT-cGMP, 1 μM) alone. The...